StockNews.com upgraded shares of Ligand Pharmaceuticals (NASDAQ:LGND – Free Report) from a sell rating to a hold rating in a research note issued to investors on Tuesday morning. Other equities ...

Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, develops and licenses biopharmaceutical assets worldwide. It offers Pradefovir, Posaconazole, Voriconazole, CAPVAXIVE, NOXAFIL ...

Ligand's Q4 2024 revenue increased by 52% year-over-year. The company reported a 40% increase in core adjusted EPS for the full year. Ligand ended 2024 with $256 million in cash and investments.

Arizona State Retirement System increased its position in shares of Ligand Pharmaceuticals Incorporated (NASDAQ:LGND – Free ...

As the U.S. stock market faces a turbulent period with major indices like the Dow Jones and S&P 500 on track for their worst week in two years, concerns about tariffs and economic health continue ...

Ligand Pharmaceuticals Inc (NASDAQ:LGND) reported a 28% increase in royalty revenue and a 40% increase in core adjusted EPS for 2024. The company has a strong financial position with over $250 ...

Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) Q4 2024 Earnings Call Transcript February 27, 2025 Ligand Pharmaceuticals Incorporated misses on earnings expectations. Reported EPS is $1.27 EPS ...

RBC Capital analyst Douglas Miehm reiterated a Buy rating on Ligand Pharma (LGND – Research Report) yesterday and set a price target of $155.00. The company’s shares closed last Friday at $122.23.

JUPITER, Fla., March 03, 2025 (GLOBE NEWSWIRE) -- Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced that Chief Executive Officer Todd Davis and Chief Financial Officer Tavo ...

The latest price target for Ligand Pharmaceuticals (NASDAQ:LGND) was reported by Benchmark on December 23, 2024. The analyst firm set a price target for $135.00 expecting LGND to rise to within 12 ...

(RTTNews) - Biopharmaceutical company Ligand Pharmaceuticals, Inc. (LGND), while reporting a loss in its fourth quarter, compared to prior year's profit, on Thursday confirmed fiscal 2025 forecast.